Trevi Therapeutics, INC 8-K filings

Trevi Therapeutics announced Q1 2026 financial results, highlighting progress in chronic cough indications and a significant capital raise extending cash runway into 2030.

Trevi Therapeutics has priced an underwritten public offering of 11.6 million shares of common stock at $13.00 per share to raise approximately $150 million in gross proceeds.

Trevi Therapeutics announced positive financial results for Q4 and full-year 2025, secured FDA alignment for its Haduvio Phase 3 program, and plans to initiate multiple clinical trials in 2026.

Trevi Therapeutics, Inc. announced the appointment of David Hastings, a seasoned biopharmaceutical executive, as its new Chief Financial Officer, effective January 6, 2026.

Trevi Therapeutics announced its third quarter 2025 financial results and provided updates on its Haduvio clinical programs, including plans for a Phase 3 initiation in early 2026.

Trevi Therapeutics announces the resignation of CFO Lisa Delfini, with CEO Jennifer L. Good assuming interim principal financial officer duties.

Trevi Therapeutics announced positive Phase 2b CORAL trial results for Haduvio in IPF chronic cough, reported strong Q2 2025 financials, and secured cash runway into 2029.

Trevi Therapeutics, Inc. announced that its stockholders approved the election of directors, ratification of auditors, executive compensation, and a significant increase in shares available under its 2019 Stock Incentive Plan at the 2025 Annual Meeting.

Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of a $100 million underwritten public offering of common stock to fund the clinical development of its investigational therapy Haduvio and extend its cash runway into 2029.

Trevi Therapeutics, Inc. has terminated the prospectus for its at-the-market (ATM) offering program with Leerink Partners, effectively pausing immediate common stock sales, though the underlying sales agreement remains active.

Trevi Therapeutics, Inc. announced overwhelmingly positive topline results from its Phase 2b CORAL clinical trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), demonstrating statistically significant reductions in cough frequency across all dose groups.

Trevi Therapeutics reports positive Phase 2a RIVER trial results and anticipates topline results from the Phase 2b CORAL trial in Q2 2025.

Trevi Therapeutics reports positive topline data from its Phase 2a RIVER trial for refractory chronic cough and provides a business update alongside its year-end 2024 financial results.

Trevi Therapeutics' Haduvio demonstrates statistically significant reduction in cough frequency in Phase 2a RIVER trial for refractory chronic cough.

Trevi Therapeutics announced the completion of patient visits in a Phase 2a trial, progress in a Phase 2b trial, and an estimated cash balance of $107.6 million as of December 31, 2024.

Trevi Therapeutics has priced a public offering of 12.5 million shares of common stock at $4.00 per share, aiming to raise $50 million before expenses.

Trevi Therapeutics announced that the sample size re-estimation for its Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough requires no change to the current sample size, with topline results expected in the first half of 2025.

Trevi Therapeutics announces promising results from a study evaluating the abuse potential of oral nalbuphine, showing statistically significant lower 'Drug Liking' compared to an active comparator.

Trevi Therapeutics reported its Q3 2024 financial results, highlighted by increased R&D spending and progress in its clinical trials for Haduvio.

Trevi Therapeutics has finished enrolling patients in its Phase 2a RIVER trial for chronic cough and anticipates releasing topline results in the first quarter of 2025.

Trevi Therapeutics announced updates on its clinical development programs, including the progress of its Phase 2b CORAL trial and the completion of its Human Abuse Potential study.

Trevi Therapeutics has appointed James Cassella as Chief Development Officer, while David Clark has stepped down as Chief Medical Officer.

Trevi Therapeutics reported its Q2 2024 financial results and provided updates on its clinical trials for Haduvio, including expected topline data readouts and a sample size re-estimation milestone.

Trevi Therapeutics held its 2024 Annual Meeting of Stockholders on June 13, 2024, where key proposals including the election of directors and ratification of the company's accounting firm were approved.

Trevi Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical trials for Haduvio, including reaffirming timelines for key data readouts.

Trevi Therapeutics reported its fourth quarter and full-year 2023 financial results, along with updates on its ongoing clinical trials for Haduvio.